Back to Investors

Investment Case

A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.

In 2024, the Group generated revenue of €2.8bn, gross profit of €428m and EBITDA of €123m. With a workforce of more than 3,500, the Group is active in Ireland, Europe, USA, APAC and MENA.

Click here to learn more